SUPPLEMENTARY MATERIAL

Published: 4 December 2025| Version 2 | DOI: 10.17632/6r7rhd49z8.2
Contributors:
Vimal H Prajapati, Vivian Laquer, Eingun James Song, Sébastien Barbarot, Lynda Spelman, Laura Huilaja, Bartlomiej Kwiek, Shilpa Aditya Goel, Ayman Grada, Tianshuang Wu, Gweneth Levy, Xiaofei Hu, Brian Calimlim, Alvaro Moreira, Kilian Eyerich

Description

Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52-Week Efficacy and Safety Results From an Open-Label Extension of the Phase 3 Heads Up Study

Files

Categories

Dermatology, Dermatitis

Funders

Licence